Advanced basal cell carcinoma.
作者： Uwe Wollina , Georgi Tchernev
DOI: 10.1007/S10354-013-0193-5
关键词:
摘要: Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure best known exogenous factor in BCC development. This also target for primary prevention. Advanced include locally advanced tumors and metastatic tumors. Prognosis worse compared to stage I II BCCs. Mohs or micrographically controlled surgery gold standard of treatment. In patients with that cannot be completely removed radiotherapy was only alternative past. More recently new drugs targeted therapy signaling pathways like sonic hedgehog epidermal growth receptor became available. small molecules are under investigation. Since complete response rates limited, future research has evaluate their combination surgery.
springer.com
sci-hub.se 参考文章(66)
Jian-Min Chang, Xiao-Man Gao, Clinical and histopathological characteristics of basal cell carcinoma in Chinese patients Chinese Medical Journal. ,vol. 126, pp. 211- 214 ,(2013)
Antonio Occhini, Marco Benazzo, Daniele Scelsi, Giulia Bertino, Niccolò Mevio, Federica Mura, Marta Tagliabue, Electrochemotherapy for the treatment of recurrent head and neck cancers: preliminary results Tumori. ,vol. 98, pp. 308- 313 ,(2012) , 10.1700/1125.12397
Chris Fellner, Vismodegib (erivedge) for advanced Basal cell carcinoma. P & T : a peer-reviewed journal for formulary management. ,vol. 37, pp. 670- 682 ,(2012)
Mark E. Burnett, Steven Q. Wang, Current sunscreen controversies: a critical review Photodermatology, Photoimmunology & Photomedicine. ,vol. 27, pp. 58- 67 ,(2011) , 10.1111/J.1600-0781.2011.00557.X
A. Lomas, J. Leonardi‐Bee, F. Bath‐Hextall, A systematic review of worldwide incidence of nonmelanoma skin cancer. British Journal of Dermatology. ,vol. 166, pp. 1069- 1080 ,(2012) , 10.1111/J.1365-2133.2012.10830.X
Sangeeta Punjabi, L. J. Cook, P. Kersey, R. Marks, R. Cerio, Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind, randomized, placebo-controlled, parallel group, multicenter study. International Journal of Dermatology. ,vol. 47, pp. 78- 82 ,(2007) , 10.1111/J.1365-4632.2007.03363.X
Uwe Wollina, Friedemann Pabst, Claudia Krönert, Johannes Schorcht, Gunter Haroske, Eckart Klemm, Thomas Kittner, High-risk basal cell carcinoma: an update Expert Review of Dermatology. ,vol. 5, pp. 357- 368 ,(2010) , 10.1586/EDM.10.27
Glen J. Weiss, Mitesh J. Borad, Christine L. Hann, Julie R. Brahmer, Howard M. Mackey, Bertram L. Lum, Walter C. Darbonne, James C. Marsters, Frederic J. de Sauvage, Jennifer A. Low, Daniel D. Von Hoff, Patricia M. LoRusso, Charles M. Rudin, Josina C. Reddy, Robert L. Yauch, Raoul Tibes, Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma New England Journal of Medicine. ,vol. 361, pp. 1164- 1172 ,(2009) , 10.1056/NEJMOA0905360
L. Bianchi, A. Orlandi, E. Campione, C. Angeloni, A. Costanzo, L.G. Spagnoli, S. Chimenti, Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. British Journal of Dermatology. ,vol. 151, pp. 148- 156 ,(2004) , 10.1111/J.1365-2133.2004.06044.X
Lorenzo Anasagasti-Angulo, Yanelda Garcia-Vega, Silvia Barcelona-Perez, Pedro Lopez-Saura, Iraldo Bello-Rivero, Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study BMC Cancer. ,vol. 9, pp. 262- 262 ,(2009) , 10.1186/1471-2407-9-262